The Latest Breaking News from Obesity

GLP-1 Drugs Did Not Lower Relapse Risk in Crohn's and Colitis Patients, a Large Claims Analysis Found

A claims study found GLP-1 drugs did not reduce IBD relapse in patients with obesity or diabetes, and did not raise safety events.

Medical Daily · Jul 29

GLP-1 Medicare Coverage: How to Get It for $50 (And the Catch)

A new CMS program finally brings Wegovy and Zepbound within reach for seniors. But a hidden rule about your deductible could cost you thousands.

Kiplinger · Jul 29

Denied Coverage For Wegovy Or Zepbound? Here Is What The Latest Value Assessment Says About Price And Access

Denied for Wegovy or Zepbound? A new value analysis explains why plans refuse coverage and what exceptions and appeals actually involve.

Medical Daily · Jul 27

Eli Lilly Cleared Two More Trials For Its Next-Generation Obesity Drug. It Will Seek FDA Approval Next Year

After 80 weeks of treatment, obese, non-diabetic participants receiving retatrutide lost an average of 22.6% of their body weight while also showing improvements in several cardiometabolic risk factors.

International Business Times · Jul 23

Heart Attack Deaths Have Fallen Dramatically Over 33 Years: A New Study Pinpoints Exactly What Worked

A JAMA Cardiology 33-year analysis found modifiable risk factors drove a dramatic decline in U.S. heart attack deaths. But BMI and blood sugar-related deaths are increasing.

Medical Daily · Jul 23

Medicare's New GLP-1 Weight Loss Drug Program Launched July 1, but It Expires in 2027 with No Successor in Place

The Medicare GLP-1 Bridge launched July 1, 2026 at $50/month for eligible beneficiaries. It expires December 31, 2027, with the permanent BALANCE replacement indefinitely delayed.

Medical Daily · Jul 23

The First Oral GLP-1 Weight Loss Pill With No Food or Injection Requirements Is Now Available

Eli Lilly's Foundayo (orforglipron) is the first oral GLP-1 obesity pill with no food or water restrictions. FDA approved it April 1, 2026. Here is what patients should know.

Medical Daily · Jul 23

The GLP-1 paradox: too expensive to cover, too effective to cut

A founder and a former HHS CTO agree: GLPs are breaking the healthcare system. We need to move away from drug-first or diet-first obesity care.

Fortune · Jul 23

Gold card health scheme to cover obesity surgery

The National Health Security Office (NHSO) has expanded benefits under the Universal Coverage Scheme, commonly known as the 30-baht gold card scheme, to include surgery for patients with severe obesity who meet strict medical criteria.

Bangkok Post · Jul 22

Type 2 Diabetes Jumped 69% in Young Women, Nearly 60% Higher Than in Men, as Obesity Starts Earlier

A study reveals a 69% rise in type 2 diabetes among young women in England since 2011, highlighting early obesity as a key factor. The NHS is responding with targeted initiatives.

International Business Times UK · Jul 22